Literature DB >> 3208800

The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.

A Howell1, J Mackintosh, M Jones, J Redford, J Wagstaff, R A Sellwood.   

Abstract

In the criteria used for assessment of response to treatment for advanced breast cancer the definition of no change (NC) is clear; however, there is no indication of the duration of stabilization required for patients to qualify for this category of response. We have made the assumption that NC is a worthwhile category of response if the overall time to progression (TTP) and survival of this group is not significantly different from patients with partial remissions (PR). Two hundred and sixty-three evaluable patients treated with endocrine therapy and 302 evaluable chemotherapy-treated patients were studied and the TTP and survival curves for PR and periods of NC from 1 to 6 months compared. For the endocrine-treated patients the TTP and survival curves for NC became non-significantly different from the PR curves after 4 and 5 months respectively. For chemotherapy-treated patients the TTP curves became non-significantly different from PR at 4 months and for survival the period was 3 months. In order to define NC as a useful category of response and to eliminate the possibility that NC taken for a shorter period could simply represent a slowly progressive tumour, we suggest that the minimum period of disease stabilization be taken as 5 months for both endocrine- and chemotherapy-treated patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208800     DOI: 10.1016/0277-5379(88)90046-6

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  16 in total

1.  High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment.

Authors:  S Pyrhönen; R Valavaara; J Vuorinen; A Hajba
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 2.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.

Authors:  Robert W Carlson; Anne O'Neill; Tatiana Vidaurre; Henry L Gomez; Sunil S Badve; George W Sledge
Journal:  Breast Cancer Res Treat       Date:  2012-03-15       Impact factor: 4.872

Review 4.  Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.

Authors:  L B Michaud; A U Buzdar
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

5.  Biological factors of prognostic significance in locally advanced breast cancer.

Authors:  J F Robertson; I O Ellis; D Pearson; C W Elston; R I Nicholson; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Prospective assessment of the role of five tumour markers in breast cancer.

Authors:  J F Robertson; D Pearson; M R Price; C Selby; J Pearson; R W Blamey; A Howell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 7.  Endpoints in advanced breast cancer: methodological aspects & clinical implications.

Authors:  Everardo D Saad
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

8.  Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Authors:  T Hamaoka; C M Costelloe; J E Madewell; P Liu; D A Berry; R Islam; R L Theriault; G N Hortobagyi; N T Ueno
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

9.  A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.

Authors:  M J Lind; B M Cantwell; M J Millward; A Robinson; M Proctor; D Simmons; J Carmichael; A L Harris
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

10.  Objective measurement of therapeutic response in breast cancer using tumour markers.

Authors:  J F Robertson; D Pearson; M R Price; C Selby; R W Blamey; A Howell
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.